YDYuefeng Du

Yuefeng Du

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yuefeng Du has a total of 53 co-authors. Here are the top co-authors by number of shared publications:

  • Juanhua Tian

    Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China

    7 shared publications
  • Lijun Mu

    Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China

    7 shared publications
  • Li Guo

    Department of Urology, the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, People’s Republic of China

    6 shared publications
  • Bing Guan

    Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China

    5 shared publications
  • Meiyu Wang

    Department of Imaging, The First Affiliated Hospital of Xi'an Jiaotong University, 710061 Xi'an, Shaanxi, China

    4 shared publications
  • Peiqiang Wu

    Department of Urology, the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, People’s Republic of China

    4 shared publications

Latest Publications

  • Open Access

    Exploratory seminal plasma metabolomics and independent HPLC–UV evaluation in men with impaired semen quality

    by Jiale Xu, Li Guo, Lingxiao Xiong, Jun Li, Peiqiang Wu, Yanmin Ma, Juan Yang, Yuefeng Du

    Background: Impaired semen quality may involve concurrent abnormalities in sperm concentration, total sperm number, motility, morphology, and DNA integrity. The corresponding alterations in the seminal plasma metabolome remain incompletely characterized. Objectives: To characterize seminal plasma metabolic alterations in men with multiple concurrent semen abnormalities and identify candidate signals associated with semen quality parameters. Materials and methods: Untargeted LC–MS/MS metabolomics was performed in a discovery cohort comprising 10 men with impaired semen quality and 9 normozoospermic controls. Candidate metabolites were screened using nominal p value and fold-change thresholds, followed by pathway and correlation analyses, post hoc ROC analysis, and qualitative comparisons with public datasets. External-calibration-derived estimates assigned to cytidine and 2-hydroxy-3-methylbutyric acid (2-HMBA) were subsequently evaluated by HPLC–UV in an independent cohort of 18 men with impaired semen quality and 18 controls. Results: Eighty-nine putatively annotated metabolites met the nominal screening criteria, but no individual metabolite remained significant after Benjamini–Hochberg false discovery rate correction. Discovery-level pathway analyses highlighted nucleotide- and nucleoside-related processes as hypothesis-generating signals. Qualitative comparison with heterogeneous publicly available reproductive metabolomics datasets provided limited directional context but was not considered formal external validation. In the independent HPLC–UV cohort, external-calibration-derived estimates assigned to 2-HMBA were nominally lower in the group with impaired semen quality (p = 0.030), but the difference did not remain significant after correction across the two candidate comparisons (q = 0.060). Cytidine showed no between-group difference (p = 0.812; q = 0.812). Discussion and conclusion: The discovery-level nucleotide-related pathway signal and the independent observation concerning 2-HMBA represent distinct lines of evidence; the latter does not validate the former. Given the small sample sizes in both the discovery and independent HPLC–UV evaluation cohorts, the absence of FDR-significant metabolites, heterogeneity across the public datasets, and limitations of the HPLC–UV assay, these findings remain exploratory and hypothesis-generating. They do not constitute quantitative validation, establish a specific mechanism, or support clinical biomarker use. Larger multicenter cohorts and targeted quantitative metabolomic analyses using validated methods are needed.

  • Open Access

    Author Correction: Leveraging cell death patterns to predict metastasis in prostate adenocarcinoma and targeting PTGDS for tumor suppression

    by Bohong Chen, Li Guo, Lihui Wang, Peiqiang Wu, Xinyu Zheng, Congzhu Tan, Na Xie, Xinyue Sun, Mingguo Zhou, Haoxiang Huang, et al.

  • Open Access

    Leveraging cell death patterns to predict metastasis in prostate adenocarcinoma and targeting PTGDS for tumor suppression

    by Bohong Chen, Li Guo, Lihui Wang, Peiqiang Wu, Xinyu Zheng, Congzhu Tan, Na Xie, Xinyue Sun, Mingguo Zhou, Haoxiang Huang, et al.

    Metastasis is the major cause of treatment failure in patients with prostate adenocarcinoma (PRAD). Diverse programmed cell death (PCD) patterns play an important role in tumor metastasis and hold promise as predictive indicators for PRAD metastasis. Using the LASSO Cox regression method, we developed PCD score (PCDS) based on differentially expressed genes (DEGs) associated with PCD. Clinical correlation, external validation, functional enrichment analysis, mutation landscape analysis, tumor immune environment analysis, and immunotherapy analysis were conducted. The role of Prostaglandin D2 Synthase (PTGDS) in PRAD was examined through in vitro experiments, single-cell, and Mendelian randomization (MR) analysis. PCDS is elevated in patients with higher Gleason scores, higher T stage, biochemical recurrence (BCR), and higher prostate-specific antigen (PSA) levels. Individuals with higher PCDS are prone to metastasis, metastasis after BCR, BCR, and castration resistance. Moreover, PRAD patients with low PCDS responded positively to immunotherapy. Random forest analysis and Mendelian randomization analysis identified PTGDS as the top gene associated with PRAD metastasis and in vitro experiments revealed that PTGDS was considerably downregulated in PRAD cells against normal prostate cells. Furthermore, the overexpression of PTGDS was found to suppress the migration, invasion, proliferationof DU145 and LNCaP cells. To sum up, PCDS may be a useful biomarker for forecasting the possibility of metastasis, recurrence, castration resistance, and the efficacy of immunotherapy in PRAD patients. Additionally, PTGDS was identified as a viable therapeutic target for the management of PRAD.


  • Open Access

    Tropisetron Ameliorated Cyclophosphamide-Induced Hemorrhagic Cystitis via Restraining TLR-4/NF-κB and JAK1/STAT3 Signaling Pathways

    by Li Guo, Chen Ma, Meiyu Wang, Yuefeng Du

    Objective: The main pathological changes of hemorrhagic cystitis (HC) ...


  • Open Access

    [Corrigendum] MicroRNA‑218 inhibits tumor angiogenesis of human renal cell carcinoma by targeting GAB2

    by Lijun Mu, Bing Guan, Juanhua Tian, Xiang Li, Qingzhi Long, Meiyu Wang, Wen Wang, Junjun She, Xudong Li, Dapeng Wu, et al.

    Subsequently to the publication of the above article, the authors have realized that the cell migration and tube formation assay data portrayed in Figs. 2 and 4 in their paper were published with some inadvertent errors. Specifically, the photograph selected for the ACHN-SFM group was accidentally misused for the 769P/LV-miR-218 group in Fig. 2F. Secondly, the photograph for the 786O/LV‑NC group in Fig. 2F was accidentally misused as the image for the 786O/shNC group in Fig. 4E; and thirdly, the photograph selected for the ACHN/shNC group in Fig. 4C was inadvertently misused for the ACHN/shNC group in Fig. 4D. These errors arose inadvertently as a consequence of the authors' mishandling their data; however, the authors were able to retrieve their original data, and have been able to reassemble these figures to show the data as was originally intended. The revised versions of Figs. 2 and 4, featuring the corrected data panels for the 769P/LV‑miR‑218 group in Fig. 2F, the ACHN/shNC group in Fig. 4D and the 786O/shNC group in Fig. 4E, are shown on the next two pages. The revised data shown for these Figures do not affect the overall conclusions reported in the paper. All the authors agree with the publication of this corrigendum. The authors are grateful to the Editor of Oncology Reports for allowing them the opportunity to publish this corrigendum, and apologize to the readership for any inconvenience caused. [Oncology Reports 44: 1961‑1970, 2020; DOI: 10.3892/or.2020.7759]


  • Open Access

    Correction: Tumor-suppressive microRNA-218 inhibits tumor angiogenesis via targeting the mTOR component RICTOR in prostate cancer

    by Bing Guan, Kaijie Wu, Jin Zeng, Shan Xu, Lijun Mu, Yang Gao, Ke Wang, Zhenkun Ma, Juanhua Tian, Qi Shi, et al.

    [This corrects the article DOI: 10.18632/oncotarget.14131.].

  • Open Access

    Development and Validation of a Nomogram for Predicting Bladder Calculi Risk in Patients With Benign Prostatic Hyperplasia

    by Euxu Xie, Xuelian Gu, Chen Ma, Li Guo, Man Li, Yuefeng Du

    Objective To develop and validate a nomogram for predicting bladder calculi risk in patients with benign prostatic hyperplasia (BPH).Methods A total of 368 patients who underwent transurethral resection of the prostate (TURP) and had histologically proven BPH from January 2018 to January 2021 were retrospectively collected. Eligible patients were randomly assigned to the training and validation datasets. Least absolute shrinkage and selection operator (LASSO) regression was used to select the optimal risk factors. A prediction model was established based on the selected characteristics. The performance of the nomogram was assessed by calibration plots and the area under the receiver operating characteristic curve (AUROC). Furthermore, decision curve analysis (DCA) was used to determine the net benefit rate of of the nomogram. Results Among 368 patients who met the inclusion criteria, older age, a history of diabetes and hyperuricemia, longer intravesical prostatic protrusion (IPP)and larger prostatic urethral angulation (PUA) were independent risk factors for bladder calculi in patients with BPH. These factors were used to develop a nomogram, which had a good identification ability in predicting the risk of bladder calculi in patients, with AUROCs of 0.911 (95% CI: 0.876–0.945) in the training set and 0.884 (95% CI: 0.820–0.948) in the validation set. The calibration plot showed that the model had good calibration. Moreover, DCA indicated that the model had a goodclinical benefit. Conclusion We developed and internally validated the first nomogram to date to help physicians assess the risk of bladder calculi in patients with BPH, which may help physicians improve individual interventions and make better clinical decisions.

  • Open Access

    MicroRNA‑218 inhibits tumor angiogenesis of human renal cell carcinoma by targeting GAB2

    by Lijun Mu, Bing Guan, Juanhua Tian, Xiang Li, Qingzhi Long, Meiyu Wang, Wen Wang, Junjun She, Xudong Li, Dapeng Wu, et al.

    Renal cell carcinoma (RCC) is one of the most common malignant cancers in the adult urinary system worldwide. Tumor angiogenesis is a critical process during cancer progression, as it modulates carcinogenesis and metastasis. In recent years, microRNA‑218 (miR‑218) has been confirmed to play a crucial role in tumor suppression. However, the role of miR‑218 in RCC angiogenesis remains unclear. In the present study, it was found that the expression of miR‑218 was decreased in RCC tumor tissues and cell lines as detected by real‑time PCR analysis. Tube formation assays and migration assays also confirmed that miR‑218 inhibited the interaction between RCC cells and vascular endothelial cells by suppressing proangiogenic factor vascular endothelial growth factor A (VEGFA) in RCC cells. miR‑218 also repressed the subcutaneous tumorigenesis of RCC cells in nude mice, and the corneal angiogenesis in rabbit eyes. The underlying molecular mechanism was elucidated; miR‑218 targets GRB2‑associated binding protein 2 (GAB2), thereby inhibiting the PI3K/AKT/mTOR/VEGFA pathway. These results provide new insights into the mechanism of RCC carcinogenesis and progression, suggesting that miRNA‑218 may be a therapeutic target for the treatment of RCC.


  • Open Access

    The miR-218/GAB2 axis regulates proliferation, invasion and EMT via the PI3K/AKT/GSK-3β pathway in prostate cancer

    by Juanhua Tian, Haibao Zhang, Lijun Mu, Meiyu Wang, Xudong Li, Xinwei Zhang, Enxu Xie, Minghai Ma, Dapeng Wu, Yuefeng Du